- Wondering if Pennant Group at US$33.26 still offers value after its recent run, or if most of the opportunity is already priced in.
- The stock has been volatile, with a 2.3% decline over the past week, a 4.0% gain over 30 days, a 19.5% return year to date and a 37.1% return over the past year, set against a 175.1% return over three years and a 26.4% loss over five years.
- These swings sit against a backdrop of ongoing interest in healthcare services companies. Investors regularly react to developments such as regulatory changes, reimbursement trends and acquisition or partnership announcements. Together, these factors often shape how the market views both the risks and the potential of operators like Pennant Group.
- Simply Wall St currently gives Pennant Group a valuation score of 3 out of 6. This score will be unpacked using several common valuation methods before turning to a more complete way to think about what the stock might be worth.
Approach 1: Pennant Group Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back to today. It focuses on the cash the business could generate for shareholders rather than short term market moves.
For Pennant Group, the 2 Stage Free Cash Flow to Equity model uses recent Free Cash Flow of about $26.34 million and then applies analyst projections and longer term estimates. Analyst forecasts feed into the early years, with Free Cash Flow projections such as $39.65 million in 2026, $54.61 million in 2027 and $73.00 million in 2028. Beyond that, Simply Wall St extrapolates cash flows out to 2035, keeping all figures in $ and below the billion range.
When all these projected cash flows are discounted back and summed, the model arrives at an intrinsic value of roughly $80.98 per share. Relative to the current share price of $33.26, the implied discount is 58.9%, which indicates that the shares screen as undervalued under this DCF approach.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Pennant Group is undervalued by 58.9%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
Approach 2: Pennant Group Price vs Earnings
For profitable companies like Pennant Group, the P/E ratio is a useful quick check, because it links what you pay per share to the earnings the business is currently generating. Investors usually accept a higher P/E when they expect stronger earnings growth and lower perceived risk, and a lower P/E when growth expectations are more modest or risks feel higher.
Pennant Group currently trades on a P/E of 38.98x, compared with the Healthcare industry average of about 21.70x and a peer group average of 88.93x. To go a step further, Simply Wall St also calculates a proprietary “Fair Ratio” of 24.78x. This Fair Ratio reflects factors such as Pennant Group’s earnings growth profile, its industry, profit margins, market cap and risk characteristics.
That Fair Ratio can be more informative than a simple industry or peer comparison, because it adjusts for company specific traits rather than assuming that all operators in the space deserve the same multiple. Setting the current P/E of 38.98x against the Fair Ratio of 24.78x suggests the shares are pricing in a higher multiple than Simply Wall St’s model implies is warranted.
Result: OVERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Pennant Group Narrative
Earlier it was mentioned that there is an even better way to understand valuation, so Narratives on Simply Wall St let you attach a clear story about Pennant Group to hard numbers such as your fair value, revenue and earnings estimates, and margin assumptions, then compare that Fair Value with the current price to help you decide if the stock fits your buy or sell criteria today.
Each Narrative connects your view of Pennant’s business, such as how you weigh demographic demand, Medicare and labor risks, or the impact of the AMED assets, to a forecast and a Fair Value that sits alongside other community views on the Pennant Group Community page. These Narratives update automatically when new data, news or earnings are added to the platform.
For example, one Pennant Group Narrative might lean closer to the higher fair value area around US$40.00 if you think earnings and margins can support that. Another might sit nearer the lower US$28.00 end if you are more focused on reimbursement and cost risks. Seeing those scenarios side by side makes it easier to decide which story aligns with your own expectations before you act.
Do you think there's more to the story for Pennant Group? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com